3 Growth Stocks Worth $5,000 of Your Money -- Even in This Market

The article recommends three underappreciated growth stocks: Credo Technology (AI data center connectivity), Cellebrite (law enforcement digital evidence software), and TransMedics (organ transplant preservation technology). Each company is positioned in large, expanding markets with limited competition and strong fundamentals.

06/05/2026, 8:20 AM • The Motley Fool

Bears Pounce On Avis Budget, Lucid, MARA — Short Interest In These 10 Stocks Soars Above 40%

Short sellers are heavily targeting 10 stocks with short interest exceeding 40% of float. Choice Hotels and Avis Budget lead with over 50% short interest, while Lucid Group, Hertz Global, and crypto/semiconductor plays like Marathon Digital and CleanSpark also face significant bearish positioning. Traders are watching for potential squeeze opportunities if positive catalysts emerge.

04/14/2026, 3:10 PM • Benzinga

TransMedics Stock Is Up 104% Over the Last Year: Is It Too Late to Buy for 2026?

TransMedics Group has surged 104% over the past year as it dominates the organ transplant industry with its innovative Organ Care System and National OCS Program. Despite trading at a premium 56x forward earnings and facing significant short interest (25% of float), the company's strong growth (32% quarterly sales growth), expanding moat through vertical integration, and international expansion opportunities suggest the valuation may be justified for long-term investors.

03/08/2026, 5:22 AM • The Motley Fool

Is Joby Aviation Stock a Buy Right Now?

Joby Aviation's stock has fallen 25% year-to-date and is trading 50% below 2025 highs at $9.56. While the lower price may seem attractive, the company's $9.4 billion market cap is still higher than established competitors like American Airlines, Lyft, and TransMedics despite having no commercial operations yet. The analyst recommends caution, noting the stock appears priced for perfection given Joby's unproven eVTOL air taxi business model and pending FAA certification.

03/07/2026, 4:30 PM • The Motley Fool

Got $5,000? TransMedics Could Be a High‑Tech Organ Transplant Moonshot

TransMedics Group (TMDX) is revolutionizing organ transplantation with its Organ Care System (OCS), which significantly improves organ utilization rates compared to traditional cold storage methods. The company has shown strong financial growth and recently built its own dedicated aircraft transportation network to address logistics challenges. However, investors should be aware of regulatory risks and the high costs of maintaining its fleet.

02/28/2026, 12:30 PM • The Motley Fool

These 10 Stocks Could Be Short Squeeze Targets: Lucid, Kohl's, Avis and More

The article identifies 10 heavily shorted stocks that could be potential short squeeze targets as of February 2, 2026. It explains how short squeezes work as a volatile feedback loop where rising stock prices force short sellers to cover positions, creating explosive gains. The most shorted stocks include Choice Hotels (56.33%), Lucid Group (54.45%), and Avis Budget Group (52.38%), among others. The article cautions that while monitoring short interest can help identify squeeze opportunities, timing such trades is extremely challenging and investors should conduct due diligence as volatility often reflects underlying business risks.

02/02/2026, 2:08 PM • Benzinga

Stocks to Love in 2026

Motley Fool contributors discuss investment opportunities for 2026 across three sectors: space companies (Rocket Lab, Redwire), healthcare/medtech (TransMedics Group), and telehealth disruption (Hims & Hers). The space sector is highlighted as a potential growth area with SpaceX's anticipated IPO, while healthcare picks focus on innovative business models transforming traditional markets.

01/11/2026, 11:04 PM • The Motley Fool

Top 10 Most Shorted Stocks: Lucid, MARA, Hims and More

The article identifies the top 10 most heavily shorted stocks as of December 29, 2025, led by Lucid Group with 54.51% short interest, followed by Choice Hotels and Avis Budget Group. Short sellers believe these companies are overvalued, while bullish traders view high short interest as potential short squeeze opportunities. The list includes stocks with market caps above $2 billion and free floats above 5 million shares.

12/29/2025, 10:30 AM • Benzinga

Looking For A Squeeze? Top 10 Most Shorted Stocks Right Now

Analysis reveals top 10 most shorted stocks, highlighting companies with high short interest percentages and potential for market volatility. Traders are monitoring these stocks for potential short squeeze opportunities.

12/10/2025, 11:42 AM • Benzinga

4 Growth Stocks to Buy After the Recent Crash

The article highlights four beaten-down growth stocks that are considered attractive investment opportunities before the year ends, with the author suggesting they trade at reasonable valuations.

11/18/2025, 5:15 AM • The Motley Fool

2 Strong Healthcare Stock Picks for Growth Investors

The article highlights two promising healthcare stocks for growth investors: TransMedics Group and Hims & Hers Health. Both companies are expanding their services and showing strong financial performance in innovative healthcare markets.

11/13/2025, 8:15 AM • The Motley Fool

2 Outstanding Healthcare Stocks to Buy and Hold for a Decade

Two healthcare companies, HCA Healthcare and TransMedics Group, show promising long-term potential due to their innovative strategies, market positioning, and ability to adapt to industry changes.

10/08/2025, 9:37 AM • The Motley Fool

Investigation Alert: Elanco Animal Health Incorporated, Driven Brands Holdings, Hasbro, and TransMedics: Johnson Fistel, PLLP Investigates Claims on Behalf of Investors

Law firm Johnson Fistel is investigating potential legal violations by officers of several companies, including Elanco, Driven Brands, Hasbro, and TransMedics, alleging false statements, misleading investors, and potential corporate governance issues.

08/27/2025, 2:16 PM • GlobeNewswire

Organ Care Products Market Valuation Set to Surpass US$ 812.12 Million By 2033 | Astute Analytica

The global organ care products market is projected to grow from $199.20 million in 2024 to $812.12 million by 2033, driven by technological innovations in organ preservation, increasing transplant volumes, and strategic investments in advanced perfusion systems.

08/04/2025, 12:30 PM • GlobeNewswire

Why TransMedics Stock Is Skyrocketing Today

TransMedics reported impressive Q2 results with 38% revenue growth, doubled earnings per share, and raised full-year sales guidance. The company's Organ Care System continues to show promise in organ transplant technology, with potential for further international market expansion.

07/31/2025, 1:16 PM • The Motley Fool